9-O-Methyl-4-hydroxyboeravinone BCAS# 333798-10-0 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 333798-10-0 | SDF | Download SDF |
| PubChem ID | 487168 | Appearance | Powder |
| Formula | C18H14O7 | M.Wt | 342.3 |
| Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 4,6,11-trihydroxy-9-methoxy-10-methyl-6H-chromeno[3,4-b]chromen-12-one | ||
| SMILES | CC1=C(C=C2C(=C1O)C(=O)C3=C(O2)C(OC4=C3C=CC=C4O)O)OC | ||
| Standard InChIKey | HTLOGFXLFFWJOX-UHFFFAOYSA-N | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. 9-O-Methyl-4-hydroxyboeravinone B is a promising candidate for cancer therapy. |
9-O-Methyl-4-hydroxyboeravinone B Dilution Calculator
9-O-Methyl-4-hydroxyboeravinone B Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.9214 mL | 14.6071 mL | 29.2141 mL | 58.4283 mL | 73.0353 mL |
| 5 mM | 0.5843 mL | 2.9214 mL | 5.8428 mL | 11.6857 mL | 14.6071 mL |
| 10 mM | 0.2921 mL | 1.4607 mL | 2.9214 mL | 5.8428 mL | 7.3035 mL |
| 50 mM | 0.0584 mL | 0.2921 mL | 0.5843 mL | 1.1686 mL | 1.4607 mL |
| 100 mM | 0.0292 mL | 0.1461 mL | 0.2921 mL | 0.5843 mL | 0.7304 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Theaflavine-3,3'-digallate
Catalog No.:BCN5420
CAS No.:33377-72-9
- Gliquidone
Catalog No.:BCC5003
CAS No.:33342-05-1
- Trianthenol
Catalog No.:BCN7802
CAS No.:333361-85-6
- NBD-556
Catalog No.:BCC1790
CAS No.:333353-44-9
- NBD-557
Catalog No.:BCC1791
CAS No.:333352-59-3
- Boc-Phe(4-NO2)-OH
Catalog No.:BCC3275
CAS No.:33305-77-0
- Dipsacoside B
Catalog No.:BCN5940
CAS No.:33289-85-9
- Gummiferin
Catalog No.:BCN8381
CAS No.:33286-30-5
- Diltiazem HCl
Catalog No.:BCC4901
CAS No.:33286-22-5
- 5,6-Dihydroyangonin
Catalog No.:BCN3566
CAS No.:3328-60-7
- 5-Aminofluorescein
Catalog No.:BCC8733
CAS No.:3326-34-9
- ML SA1
Catalog No.:BCC6276
CAS No.:332382-54-4
- Z-Asp(OtBu)-OSu
Catalog No.:BCC2787
CAS No.:3338-32-7
- 8-Deoxygartanin
Catalog No.:BCN5255
CAS No.:33390-41-9
- Gartanin
Catalog No.:BCN5256
CAS No.:33390-42-0
- LUF 5834
Catalog No.:BCC6237
CAS No.:333962-91-7
- (E)-2-Decenoic acid
Catalog No.:BCC1292
CAS No.:334-49-6
- Spermidine trihydrochloride
Catalog No.:BCC6865
CAS No.:334-50-9
- 3-Hydroxy-3-acetonyloxindole
Catalog No.:BCN4069
CAS No.:33417-17-3
- Etoposide
Catalog No.:BCC1151
CAS No.:33419-42-0
- Quercetin 3,4'-dimethyl ether
Catalog No.:BCN5257
CAS No.:33429-83-3
- 2-Pyridylethylamine dihydrochloride
Catalog No.:BCC7379
CAS No.:3343-39-3
- 3,3'-Bilawsone
Catalog No.:BCN7912
CAS No.:33440-64-1
- Alnustone
Catalog No.:BCN2761
CAS No.:33457-62-4
Mirabijalone E: a novel rotenoid from Mirabilis himalaica inhibited A549 cell growth in vitro and in vivo.[Pubmed:24882730]
J Ethnopharmacol. 2014 Aug 8;155(1):326-33.
ETHNOPHARMACOLOGICAL RELEVANCE: The roots of Mirabilis himalaica have been used in Tibetan folk medicine for treatment of uterine cancer, nephritis edematous, renal calculus and arthrodynia. In our previous work, the ethanol extract of roots had shown potent cytotoxicity against human cancer cells. However, no information is available on the antitumor effect of Mirabilis himalaica. The aim of the present study was to investigate the active constituents guided by bioassay and evaluate the related antitumor efficacy in vitro and in vivo. MATERIALS AND METHODS: The active subextract (ethyl acetate) was subjected to successive chemical separation using a combination of silica gel, LH-20 chromatography and semi-preparative HPLC. The structures were determined by spectroscopic analysis techniques such as nuclear magnetic resonance (NMR) and mass spectrometry. Three human cancer cell lines, A549, HepG2 and HeLa were used for in vitro cytotoxicity evaluation of all isolated compounds by MTT-assay. Then, the potent and novel compound mirabijalone E was employed to the mechanism study againstA549 cells. BrdU immunofluorescence, soft agar assay and cell cycle analysis were employed to detect the cell proliferation effects. Annexin V-FITC/PI staining assay was used for examining apoptotic effects. Expression levels of apoptosis-related proteins were determined by western blot assay. in vivo tumorigenic assay was used to evaluate the xenograft tumor growth treated with mirabijalone E. RESULTS: One new rotenoid compound, mirabijalone E, together with eight known rotenoids was isolated from Mirabilis himalaica. Mirabijalone E, 9-O-methyl-inone B, boeravinone C and boeravinone H exhibited cytotoxicity against A 549 and HeLa cells. Further study on mirabijalone E was carried out in vitro and in vivo. Mirabijalone E inhibited A549 cells growth in a time and dose-dependent manner, which arrested cell cycle in S phase. Mechanistically, mirabijalone E treatment resulted in the increase of Bax expression level, the decrease of Bcl-2 level and the activation of caspase-3, which suggested the activation of apoptosis cascades. Consequently, the xenograft treated with mirabijalone E showed markedly suppressed tumor growth. CONCLUSIONS: The result suggested that mirabijalone E, together with active compounds, 9-O-Methyl-4-hydroxyboeravinone B, boeravinone C and boeravinone H could be a promising candidate for cancer therapy.
